Mutation of FLT3 is not a general phenomenon in CD117-positive T-ALL

Citation for published version (APA):

Scharnhorst, V., Wals, J., Beverloo, H. B., Langerak, A. W., & Velden, van der, V. H. J. (2005). Mutation of FLT3 is not a general phenomenon in CD117-positive T-ALL. *Leukemia Research*, 30(2), 245-246.
<https://doi.org/10.1016/j.leukres.2005.06.018>

DOI:

[10.1016/j.leukres.2005.06.018](https://doi.org/10.1016/j.leukres.2005.06.018)

Document status and date:

Published: 01/01/2005

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

- [9] Dutta N, Majumder D, Gupta A, Mazumder DN, Banerjee S. Analysis of human lymphocyte antigen class I expression in gastric cancer by reverse transcriptase polymerase chain reaction. *Hum Immunol* 2005;66:164–9.
- [10] Pascal V, Brunet C, Pradel V, Thirion X, Andre P, Faucher C, et al. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation. *Leukemia* 2002;16:2259–66.
- [11] Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. *Br J Haematol* 2002;117:821–7.
- [12] Demanet C, Mulder A, Deney V, Worsham MJ, Maes P, Claas FH, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? *Blood* 2004;103:3122–30.

Durjoy Majumder
Subrata Banerjee*

*Biophysics Division, Structural Genomics Section
Saha Institute of Nuclear Physics
1/AF Bidhannagar, Kolkata 700064, India*

Debasis Bandyopadhyay
Sarmila Chandra
*Hematology Section, Park Clinic
Kolkata 700016, India*

Nandini Mukherjee
*Hematology Unit, Department of Medicine
RG Kar Medical College & Hospital
Kolkata 700037, India*

*Corresponding author. Tel.: +91 33 25565611
fax: +91 33 23374637
E-mail address: subrata.banerjee@saha.ac.in
(S. Banerjee)

2 June 2005

Available online 1 August 2005

doi: 10.1016/j.leukres.2005.06.017

Mutation of *FLT3* is not a general phenomenon in CD117-positive T-ALL

Keywords: Acute lymphoblastic leukaemia; CD117; *FLT3* mutation; Kinase inhibitor therapy

CD117 is considered to be a marker of leukemic cells committed to the myeloid lineage, however up to 11% of T-ALLs have been found to express CD117 [1]. Activating mutations in the *FLT3* gene are common in acute myeloid leukemia (AML) but are rarely found in acute lymphoblastic leukemia (ALL) [2]. Recently, a subset (3 out of 55) of adult T-ALLs characterized by expression of CD117 (in >90% of T-lymphoblasts) and *FLT3* mutations (either internal tandem duplications (ITD) in the juxtamembrane region or mutations in the activation-loop coding region) was described [3]. These data suggested that CD117 expres-

sion in T-ALL lymphoblasts might identify a subset of T-ALLs in which activating *FLT3* mutations are essential in oncogenesis. If *FLT3* mutations would be present in all CD117-positive T-ALLs, up to 11% of all T-ALL patients could potentially benefit from therapy with *FLT3* inhibitors, which are currently under investigation for AML treatment [2,4].

We report here on the *FLT3* mutation status of a 75-year-old man diagnosed with CD117-positive T-ALL. The patient presented with pancytopenia and anemia. Bone marrow analysis revealed 70% blasts with an L1 ALL morphology according to the French–American–British classification. There was no cytochemical evidence of myeloid differentiation, i.e. Sudan black B, specific and non-specific esterase stains were negative. Flowcytometry demonstrated 85% blasts, 9% T-lymphocytes, 1% B-lymphocytes, 2% granulocytes, and <1% monocytes. The blasts were classified as T-lymphoblasts based on intracytoplasmic CD3 expression (Fig. 1). Furthermore, >90% of the blast cells were positive for CD117, CD2, CD7, CD13, CD45, and CD56, whereas CD34, CD33, CD5, and CD19 were expressed on a subset of blast cells only (about 75, 30, 30 and 40% of blasts, respectively). Blast cells did not significantly express TdT, MPO, CD1a, CD4, CD8, CD10, CD14, CD15, CD22, CD65, CD133 and SmCD3 (all <10% positive). Of importance, CD135 (*FLT3*) expression was weak/negative on the T-lymphoblasts (Fig. 1).

Cytogenetics revealed a complex karyotype in 73% of metaphases: 46, XY, der(1)t(1;9)(p34;q34)t(1;3)(q22;q22), der(3)t(1;3), del(5)(q21q34), der(9)t(1;9), t(12;17)(q24;q21). The balanced translocation between chromosomes 1 and 9 might involve the *ABL* gene on 9q34. The other translocations have been observed in MDS/AML, like the del(5), or in rare cases of CML, like the t(1;3), t(1;9) and t(12;17), but have never been described in combination so far.

RT-PCR analysis showed no ITD in the *FLT3* juxtamembrane region (Exon 14 and 15) [5]. Furthermore, sequence analysis of the *FLT3* activation-loop coding region (exon 20) showed the absence of currently known activating mutations (D835, I836, 840GS, N841 and Y842C) [6].

Immunophenotypically the case presented here is an immature T-ALL expressing CD117 and CD13, comparable to the three cases described earlier [3]. However, the remaining immunophenotype of our patient showed some differences, with (partial) positivity for CD56, CD33 and CD5, and negativity for TdT. More important, our patient lacked significant CD135 expression and showed no activating *FLT3* mutations. Although we cannot exclude the presence of mutations outside exon 14, 15 and 20, our data strongly suggest that CD117-positive T-ALLs do not necessarily carry *FLT3* mutations. Apparently, CD117-positive T-ALL are more heterogeneous than previously reported [3]. Further research into the frequency of *FLT3* mutations in CD117-positive T-ALL is necessary to establish the correlation between the immunophenotype of T-lymphoblasts

Fig. 1. Immunophenotype of the T-lymphoblasts. Immunophenotyping was performed using four-color labelings and data were acquired on a FACS Calibur (BD Biosciences, San Diego, CA). (A) The T-lymphoblasts (85% of the leukocytes) showed a low side scatter and intermediate expression of CD45, which clearly distinguished them from the remaining normal lymphocytes (10%), monocytes (<1%), and granulocytes (2%). By gating on the SSC-CD45 characteristics, the immunophenotype of the T-lymphoblasts was further evaluated, showing intracytoplasmic CD3 expression in the absence of surface membrane CD3 expression (B); positivity for CD117 and CD13/CD33 (C); and no/weak expression of CD135 (D).

and *FLT3* mutations. Such analysis will finally show which percentage of patients with CD117-positive T-ALLs might benefit from therapy with *FLT3* inhibitors.

Acknowledgements

No financial support or conflicts of interest.

References

- [1] Bene MC, Bernier M, Casasnovas RO, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. *Blood* 1998;92:596–9.
- [2] Gilliland DG, Griffin JD. The roles of *FLT3* in hematopoiesis and leukemia. *Blood* 2002;100:1532–42.
- [3] Paietta E, Ferrando AA, Neuberg D, et al. Activating *FLT3* mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. *Blood* 2004;15(104):558–60.
- [4] Levis M, Small D. *FLT3*: ITDoes matter in leukemia. *Leukemia* 2003;17:1738–52.
- [5] Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the *FLT3* gene found in acute myeloid leukemia. *Leukemia* 1996;10:1911–8.
- [6] Frohling S, Schlenk RF, Breitnick J, et al., AML Study Group Ulm. Acute myeloid leukemia. Prognostic significance of activating *FLT3* mutations in younger adults (16–60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. *Blood* 2002;100:4372–80.

Volkher Scharnhorst*

Jaap Wals

*Clinical Chemistry and Hematology Laboratory,
Atrium Medical Center, P.O. Box 4446, 6401 CX Heerlen
The Netherlands*

H. Berna Beverloo

Anton W. Langerak

Vincent H.J. van der Velden

Erasmus MC, University Medical Center,

Rotterdam, The Netherlands

* Corresponding author. Tel.: +31 45 5766666;

fax: +31 45 5766575.

E-mail address: v.scharnhorst@atriummc.nl

(V. Scharnhorst)

4 June 2005

Available online 2 August 2005

doi: 10.1016/j.leukres.2005.06.018